On October 6, 2026, an attacker exploited Onyx DAO's governance system to transfer 620 million XCN tokens, worth about $2.91 million, from its Ethereum treasury to attacker-controlled wallets. The attacker managed to pass a malicious governance proposal and bypassed all governance checks, including a two-day timelock designed to prevent such exploits. This incident highlights risks in decentralized governance, especially when voting power is concentrated, and may prompt Onyx to strengthen its security measures, such as multi-signature requirements or stricter voting protocols. Onyx has faced similar security issues before, with losses exceeding $3.8 million in past years, emphasizing the need for ongoing community vigilance and improved governance safeguards.
The Onyx DAO treasury's recent movement of 620 million XCN tokens is notable context for readers. For those tracking the broader cryptocurrency market, here is Pluang's snapshot as of Oct 07, 2026 03:33 WIB: out of 50 major cryptocurrencies, 12 rose and 37 fell today. Among them, ZIL (Zilliqa) declined by 3.52% to Rp63 with a typical hold time of 133 days and a buy order activity of 72%, CRV (Curve DAO Token) dropped 3.47% to Rp6,488 with 55% sell orders, and MANA (Decentraland) decreased 3.13% to Rp1,827 with 71% buy orders.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
